Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
Level 1 - systematic review of randomized trials
Meta-analysis of 147 randomized controlled trials
PubMed 40618457 · doi:10.1016/j.atherosclerosis.2025.120420
What was done
A systematic review and meta-analysis conducted according to PRISMA guidelines evaluated the effect of lipid-lowering therapies versus placebo on plasma lipoprotein(a) [Lp(a)] levels. Included studies were English-language phase II, III, or IV randomized controlled trials in adults with an intervention duration exceeding 3 weeks. Between-group absolute mean differences and 95% confidence intervals were calculated separately for each drug class across 147 RCTs encompassing 145,314 participants.
What was found
Statins, bempedoic acid, ezetimibe, omega-3 fatty acids, and fibrates showed no significant effect on Lp(a) concentrations. In contrast, significant Lp(a) reductions were observed with: - PCSK9 monoclonal antibodies: -6.37 mg/dL (95% CI: -7.26 to -5.47; 29% relative reduction) - Inclisiran: -4.76 mg/dL (95% CI: -5.83 to -3.69; 22% relative reduction) - CETP inhibitors: -6.77 mg/dL (95% CI: -8.67 to -4.88; 46% relative reduction) - Niacin: -7.06 mg/dL (95% CI: -9.27 to -4.85; 37% relative reduction) Subgroup analyses indicated that higher baseline Lp(a) concentrations were associated with larger absolute reductions for PCSK9 monoclonal antibodies, inclisiran, and CETP inhibitors.
Why it matters
This comprehensive synthesis clarifies which lipid-lowering drug classes meaningfully lower Lp(a), showing that standard treatments like statins and ezetimibe have no effect, while PCSK9-targeted therapies, CETP inhibitors, and niacin yield modest-to-moderate reductions.
Limits
The analysis evaluates a surrogate biomarker (circulating Lp(a) concentration) rather than hard clinical cardiovascular endpoints, leaving uncertain whether these magnitude reductions translate to clinical risk reduction. The search was limited to English-language trials, and variations in assay methods across trials were not detailed in the abstract.